Yes, they would qualify as orphan indications and potentially benefit from NNZ-2591 but prevalence seems to be quite low.
For example, for trisomy 18, only 5- 10% of babies born with the condition survive beyond 12 months. The survival rate seems to be higher for monosomy 18p but prevalence is still lower than for Pitt Hopkins syndrome.
Neuren Media and Analyst Coverage, page-1226
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
-0.160(1.02%) |
Mkt cap ! $2.019B | |||
| Open | High | Low | Value | Volume |
| $15.88 | $15.93 | $15.41 | $2.041M | 130.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 153 | $15.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.60 | 156 | 4 |
View Market Depth
| Last trade - 12.35pm 28/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |